The FDA approved Wegovy 7.2 mg on March 19, 2026, but no randomized head-to-head against tirzepatide at that dose has been published
About 10% of tirzepatide participants had a heart-rate increase above 20 bpm during escalation, compared with 3% on placebo. A lean Japanese cohort reached +10 to +13 bpm, and 23% of Japanese participants at 15 mg crossed the abnormal-pulse threshold versus 7% of other participants, despite only 17% higher exposure. Lean and East Asian bodies showed greater cardiovascular sensitivity than exposure alone predicted
But cost should be weighed alongside the other factors below, not treated as the only variable
Asadi M, Taghizadeh S, Kaviani E, Vakili O, Taheri-Anganeh M, Tahamtan M, et al
Important Considerations for Administration Semaglutide is given as an injection under the skin, typically in the thigh, stomach, or upper arm